Table 1.
General characteristics of patients evaluated.
| Patients (%) | Median Age in Years (IQR) | Median Follow-Up in Months (IQR) | Males (% by Group) | Cys (% by Group) | TAC (% by Group) | CNIs and Other ISTs (% by Group) | COVID-19 (%) | Median Age in Years (IQR) | Median Follow-Up in Months (IQR) | Males (% by Group) | Cys (% by Group) | TAC (% by Group) | CNIs and Other ISTs (% by Group) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RMDs | 53 (14) | 61 (48-69) | 41 (17–81) | 15 (28) | 53 (100) | 0 (0) | 30 (57) | 0 (0) | - | - | - | - | - | - |
| Lung Tx | 91 (24) | 58 (48-64) | 116 (46–187) | 54 (59) | 11 (12) | 80 (88) | 91 (100) | 3 (21) | 65 (62–75) | 60 (1–266) | 2 (67) | 1 (33) | 2 (67) | 3 (100) |
| Heart Tx | 100 (26) | 63 (53-72.5) | 144 (72–228) | 61 (61) | 63 (63) | 37 (37) | 78 (78) | 5 (36) | 63 (53–67) | 60 (48–144) | 3 (60) | 2 (40) | 3 (21) | 3 (60) |
| Kidney Tx | 140 (36) | 55 (48-62.5) | 62.5 (32.5–116.5) | 90 (64) | 43 (31) | 97 (69) | 139 (99) | 6 (43) | 57.5 (51–64) | 95 (46–159) | 5 (83) | 3 (50) | 3 (21) | 5 (83) |
| Overall | 384 (100) | 58 (49-66) | 83.5 (39–156) | 220 (57) | 170 (44) | 214 (56) | 338 (88) | 14 (100) | 60.5 (46–159) | 62.5 (53–67) | 10 (71) | 6 (43) | 8 (57) | 11 (79) |
COVID-19: coronavirus disease 2019; IQR: interquartile range; Tx: transplantation; Cys: cyclosporine; TAC: tacrolimus; RMDs: rheumatic diseases; ISTs: immunosuppressive treatments.